Clinical Trials Directory

Trials / Completed

CompletedNCT00065182

Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer

WEEKLY IV TOPOTECAN/DOCETAXEL COMBINATION COMPARED TO DOCETAXEL IN PATIENTS WITH PRETREATED ADVANCED NSCLC: AN OPEN-LABEL MULTICENTER RANDOMIZED PHASE III TRIAL

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
399 (actual)
Sponsor
GlaxoSmithKline · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to compare the efficacy and safety of a weekly regimen of two FDA approved drugs in combination versus one FDA approved drug in subjects with advanced non-small cell lung cancer who have received one previous chemotherapy excluding TAXOTERE or HYCAMTIN.

Conditions

Interventions

TypeNameDescription
DRUGTopotecan/Docetaxel combination
DRUGDocetaxel

Timeline

Start date
2003-08-14
Primary completion
2007-08-30
Completion
2007-08-30
First posted
2003-07-18
Last updated
2019-06-24
Results posted
2019-06-24

Locations

85 sites across 3 countries: United States, Canada, Poland

Source: ClinicalTrials.gov record NCT00065182. Inclusion in this directory is not an endorsement.